The GLP‑1 story is starting to look bigger than appetite
A randomized Lancet trial found that semaglutide plus therapy reduced heavy drinking days in people with alcohol use disorder and obesity, adding momentum to the idea that GLP‑1 drugs may affect reward behavior as well as weight.